$PLYX News

Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial

Raymond James Initiates Coverage On Polaryx Therapeutics with Strong Buy Rating, Announces Price Target of $6

LUCID CAPITAL MARKETS Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $7

HC Wainwright & Co. Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $7

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial

Why Polaryx Therapeutics Stock Is Surging On Thursday?

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

Polaryx Therapeutics Says FDA Grants Fast Track Designation To PLX-200 For Treatment Of JNCL/CLN3 Disease, Krabbe Disease, And Sandhoff Disease

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care

Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference

Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)

Polaryx Therapeutics Says FDA Grants Fast Track Designation To PLX-200 For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis

Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events

Maxim Group Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $10

Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders

What's Going On With Polaryx Therapeutics Stock Wednesday?

Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial

Polaryx shares are trading higher after the company announced it selected a contract research organization for SOTERIA to evaluate PLX-200, across four different LSDs.